Search results
40 Results for 'Gene Expression'
- Technologies (3)
- Collaborations (0)
- Team (0)
- News (25)
- Events (0)
- Multimedia (12)
- Publications (0)
- Jobs (0)
Technologies 3
-
CogniXense for Rare Disease Drug Discovery
Unravel Biosciences has licensed a Wyss drug discovery platform technology to identify and create drugs to treat complex central nervous system disorders, starting with Rett syndrome. -
Engineered Live Biotherapeutic Product (eLBP) to Protect the Microbiome from Antibiotics
eLBP is a safe and cost-effective therapeutic for patients treated with beta-lactam antibiotics that safeguards against the loss of health-essential microbes while preventing the development and spread of antibiotic resistance. -
CogniXense: A Platform for Rapid Drug Repurposing
CogniXense is a target-agnostic drug discovery platform that enables the repurposing of drugs for rare genetic diseases in record time. By combining human data-based computational drug prediction with on-demand animal model development, we can mimic the diversity of symptoms of patient populations and begin drug screening on new diseases within a month.
News 25
Multimedia 12
-
Video/AnimationLight-Seq: Light-Directed In Situ Barcoding of BiomoleculesThis animation explains how the Light-Seq technology works to barcode and deep-sequence selected cell populations in tissue samples, and how the team applied it to the analysis of distinct and rare cells in the mouse retina. Credit: Wyss Institute at Harvard University. -
Audio/PodcastIlluminating Biological Context with Josie Kishi – Translation by Fifty YearsTechnologies like next-generation sequencing allow us to understand which RNA transcripts and proteins are expressed in biological tissues. However, it’s often equally important to understand how cells or molecules are positioned relative to one another! Whether it be a cell changing its shape, an organelle ramping up a metabolic process, or a DNA molecule traveling... -
Video/AnimationBeating Back the Coronavirus: FDA-Approved Drug Repurposing PipelineWith the goal of rapidly repurposing FDA-approved drugs to treat COVID-19, the Wyss Institute is collaborating with the Frieman Lab at the University of Maryland Medical School and the tenOever Lab at the Icahn School of Medicine at Mount Sinai to establish a multidisciplinary pipeline that can rapidly predict, test, and validate potential treatments. Credit:... -
Video/AnimationCogniXense: Speeding Up Treatments for Rare DiseasesAt the Wyss Institute, we are tackling Rett syndrome, a rare disease that affects 1 out of 9,000 children, by developing a scalable model for neurodevelopmental and cognitive diseases. This model can test drugs to see which will improve memory, learning, and behavior, with the end goal of finding effective therapies. Credit: Wyss Institute at... -
Video/AnimationSoft Robotic Gripper for Jellyfish 2.0Scientists from the Wyss Institute at Harvard University and CUNY have created ultra-soft robotic grippers that resemble fettuccini noodles to safely catch and release delicate underwater creatures like jellyfish without harm. Credit: Wyss Institute at Harvard University -
Video/AnimationLighting up proteins with Immuno-SABERThis animation explains how Immuno-SABER uses the Primer Exchange Reaction (PER) to enable the simultaneous visualization of multiple proteins in tissues in different applications. Credit: Wyss Institute at Harvard University.